Equity Overview
Price & Market Data
Price: $1.74
Daily Change: -$0.07 / 4.02%
Range: $1.69 - $1.87
Market Cap: $588,655,040
Volume: 8,955,051
Performance Metrics
1 Week: -30.24%
1 Month: -20.28%
3 Months: -19.16%
6 Months: -36.16%
1 Year: -39.30%
YTD: -34.96%
Company Details
Employees: 220
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; and NUV-868, a binding domain 2 bromodomain and extra-terminal inhibitor that inhibits bromodomain-containing protein 4. The company was founded in 2018 and is headquartered in New York, New York.